Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Anchiano Therapeutics Ltd ADR (ANCN)

Anchiano Therapeutics Ltd ADR (ANCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Anchiano Therapeutics Ltd ADR ONE KENDALL SQUARE BUILDING 400 SUITE 14-105 JERUSALEM L3 9777401 ISR

www.anchiano.com P: 857-259-4622

Description:

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapies to treat cancer. The company's product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. It operates primarily in Cambridge, MA and Jerusalem, Israel. Anchiano Therapeutics Ltd. is based in CAMBRIDGE.

Key Statistics

Overview:

Market Capitalization, $K 34,948
Shares Outstanding, K 7,420
Annual Sales, $ 0 K
Annual Net Income, $ -11,610 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,140 K
60-Month Beta 0.95
% of Insider Shareholders 6.88%
% of Institutional Shareholders 1.94%
Float, K 6,909
% Float 93.12%

Growth:

1-Year Return 622.84%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/06/21
Earnings Per Share ttm -1.46
EPS Growth vs. Prev Qtr 28.57%
EPS Growth vs. Prev Year -112.56%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-16 on 03/17/21

ANCN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -152.75%
Return-on-Assets % -112.00%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 9.77
Book Value/Share 0.48
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar